 Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement C5 or leukotriene LTB4 systems, or both complement and leukotrienes together, play a primary role in disease progression, a growing area of clinical interest. Akaris lead drug candidate, nomacopan formerly known as Coversin, is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 LTB4 activity. 